Talus
Facts
- HQ
- Seattle, USA
- Sectors
- Biotechnology, Drug discovery, Healthcare
- Stage
- Seed
Flexe Names Pirasenna Thiyagarajan CTO; Talus Bioscience Appoints Gaelle Mercenne Amid $11.2M Funding; Vouched Adds David McGrath as Sales VP
Flexe appointed Pirasenna Thiyagarajan as chief technology and product officer following CTO David Glick's departure. Talus Bioscience hired Gaelle Mercenne as head of biology after securing $11.2 million in funding, while Vouched named David McGrath as vice president of sales amid leadership changes.
Pack Ventures Seeks $30M for Second Fund to Invest in University of Washington-Linked Startups
Pack Ventures, a venture capital fund focused on University of Washington-linked startups, raised $5 million for its first fund and is now aiming to raise $30 million for a second fund to expand its investments. The firm has established a preferred partnership with UW and co-invests with other Seattle VCs in companies across life sciences, software, and healthcare sectors.
Talus Bioscience Raises $11.2M to Develop Drugs Targeting Undruggable Gene-Regulating Proteins
Seattle biotech Talus Bioscience raised $11.2 million in venture capital to advance its drug discovery platform targeting undruggable gene-regulating proteins linked to diseases. Founded in 2020 by Alex Federation and Lindsay Pino, Talus uses its MARMOT platform and machine learning to study transcription factors within living cells.
Talus Bioscience Secures $4.3M in Grants to Advance Gene Activity Drug Discovery Platform
Seattle-based biotech startup Talus Bioscience secured $4.3 million in non-dilutive grants from the Andy Hill Cancer Research Endowment and the SBIR program to advance its drug discovery platform targeting gene activity through transcription factors. The startup, led by CEO Alex Federation and CTO Lindsay Pino, has raised a total of $7 million in venture funding and $7.3 million in grants since its founding in 2020.
